Doxorubicin and selenium cooperatively induce Fas signaling in the absence of Fas/Fas ligand interaction

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3075-3082

  Li, Song ^a   Zhou, Yunfei ^b   Dong, Yan ^a   Ip, Clement ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Caspase 8; Death receptor pathway; Doxorubicin; Selenium

Indexed keywords

CASPASE 8; DOXORUBICIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; METHYLSELENINIC ACID; SELENIUM; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 8; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; IMMUNOPRECIPITATION; ORGANOSELENIUM COMPOUNDS; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 35349019259     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N and Simes J: Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev CD003367, 2004.
2. Li S, Zhou Y, Wang R, Zhang H, Dong Y and Ip C: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 6: 1031-1038, 2007.
3. Herr I, Wilhelm D, Bohler T, Angel P and Debatin KM: Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16: 6200-6208, 1997.
4. Houghton JA, Harwood FG and Tillman DM: Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 94: 8144-8149, 1997.
5. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1: 543-551, 1998.
6. Kasibhatla S, Beere HM, Brunner T, Echeverri F and Green DR: A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc. Curr Biol 10: 1205-1208, 2000.
7. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620, 2000.
8. Walczak H and Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256: 58-66, 2000.
9. Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA and Schwarz T: Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 140: 171-182, 1998.
10. Micheau O, Solary E, Hammann A and Dimanche-Boitrel MT: Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274: 7987-7992, 1999.
11. Tang D, Lahti JM, Grenet J and Kidd VJ: Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J Biol Chem 274: 7245-7252, 1999.
12. Chen Y and Lai MZ: c-Jun NH2-terminal kinase activation leads to a FADD-dependent but Fas ligand-independent cell death in Jurkat T cells. J Biol Chem 276: 8350-8357, 2001.
13. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282: 290-293, 1998.
14. Rehemtulla A, Hamilton CA, Chinnaiyan AM and Dixit VM: Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem 272: 25783-25786, 1997.
15. Wesselborg S, Engels IH, Rossmann E, Los M and Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93: 3053-3063, 1999.
16. Krueger A, Baumann S, Krammer PH and Kirchhoff S: FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254, 2001.
17. Fulda S, Meyer E and Debatin KM: Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by downregulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 60: 3947-3956, 2000.
18. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L and Johnston PG: c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25: 838-848, 2006.
19. Singh TR, Shankar S, Chen X, Asim M and Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400, 2003.
20. Ghose A, Fleming J, El-Bayoumy K and Harrison PR: Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compoumds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res 61: 7479-7487, 2001.
21. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P and Kolenko VM: Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 24: 5868-5877, 2005.
22. Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937, 2002.
23. Suhara T, Kim HS, Kirshenbaum LA and Walsh K: Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 22: 680-691, 2002.
24. Ip C, Thompson HJ, Zhu Z and Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60: 2882-2886, 2000.
25. Tanaka Y, Ueda K, Ozawa T, Kitajima I, Okamura S, Morita M, Yokota S and Imanaka T: Mutation study of antithrombin: the roles of disulfide bonds in intracellular accumulation and formation of russell body-like structures. J Biochem (Tokyo) 137: 273-285, 2005.
26. Goldberg GS, Jin Z, Ichikawa H, Naito A, Ohki M, el Deiry WS and Tsuda H: Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis. Cancer Res 61: 1334-1337, 2001.
27. Powell WC, Fingleton B, Wilson CL, Boothby M and Matrisian LM: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9: 1441-1447, 1999.
28. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A and Tschopp J: Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213, 1998.
29. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J and Norris JS: Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2: 348-358, 2000.
30. Chinnaiyan AM, O'Rourke K, Tewari M and Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512, 1995.
31. Kuang AA, Diehl GE, Zhang J and Winoto A: FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 275: 25065-25068, 2000.
32. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El Deiry WS, Lowe SW, Goeddel DV and Mak TW: FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279: 1954-1958, 1998.
33. Zhang J, Cado D, Chen A, Kabra NH and Winoto A: Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296-300, 1998.
34. Gil J and Esteban M: The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene 19: 3665-3674, 2000.
35. Tourneur L, Buzyn A and Chiocchia G: FADD adaptor in cancer. Med Immunol 4: 1-9, 2005.